A Beginner's Guide to Microdosing

Microdosing means taking a very small, carefully measured amount of a psychedelic substance — typically one-tenth to one-twentieth of a standard dose — on a regular schedule. The dose is small enough that it produces no hallucinations, no impairment, and no obvious psychedelic effect. The goal is subtle: a quiet shift in mood, focus, or wellbeing that's felt rather than seen.

Over the past decade, microdosing has moved from a niche practice discussed in online forums to a mainstream conversation — covered in the New York Times, studied at major research universities, and tried by a growing number of people looking for alternatives to conventional mental health treatment.

Here's what it actually is, how it works, and what the evidence says.

The idea of taking psychedelics in small, functional doses isn't new. Researchers experimented with low-dose psychedelics in the 1950s and 60s, and Albert Hofmann — the Swiss chemist who first synthesized LSD in 1938 — reportedly microdosed in his later years, describing it as a tool for clarity and focus.

But the modern practice of microdosing was largely shaped by James Fadiman, a Stanford-trained psychologist and researcher who spent years collecting self-reports from people experimenting with sub-perceptual doses. His 2011 book The Psychedelic Explorer's Guide introduced a structured approach — one dose every three days — to a wide audience, and the protocol he outlined became the default starting point for most microdosers.

The practice got its biggest cultural boost around 2015, when tech workers in Silicon Valley began openly discussing microdosing as a productivity and creativity tool. The framing was secular and functional — less about spiritual exploration, more about performance. That reframing brought a new audience to a practice that had previously lived on the fringes.

The two most common are psilocybin mushrooms and LSD. Each has practical differences worth knowing.

Dried fungi containing the psychoactive compound psilocybin — have become the more popular choice in recent years, partly because of growing legal access in decriminalized cities and states, and partly because the effects are generally considered gentler and shorter-lasting than LSD. A typical microdose is between 0.1 and 0.3 grams of dried mushrooms. Precise dosing is difficult because potency varies between batches and strains, which is one of the practical challenges microdosers frequently cite.

Lysergic acid diethylamide, known as LSD or acid, produces a slightly longer experience than psilocybin and has a more consistent potency, which makes dosing easier in theory. A typical microdose is between 5 and 20 micrograms, compared to a standard recreational dose of 75 to 150 micrograms. LSD remains illegal in most jurisdictions with no decriminalization carve-outs.

Less commonly, people microdose other substances — DMT in the form of ayahuasca, mescaline, or ibogaine — but these are niche compared to psilocybin and LSD, and far less studied.

[INTERNAL LINK: Microdosing LSD vs. Psilocybin: What's the Difference?]

This is where language gets slippery, because a true microdose is designed to be sub-perceptual — meaning you're not supposed to feel much at all in an obvious sense.

What most experienced microdosers describe is a subtle backdrop: a slight brightening of mood, a little more ease in conversation, less friction when starting a task. Some describe it as the mental equivalent of a good night's sleep — not a peak state, just a removal of a low-grade drag that they hadn't fully noticed before.

What a microdose should not feel like is any of the following: visual distortion, altered perception of time, a "high," or any impairment in normal functioning. If those effects are present, the dose is too high. The sub-perceptual threshold is the point. Going above it means you've taken a low recreational dose, not a microdose.

A protocol is simply a schedule — how often to dose, when to rest, and how long to run a cycle before stopping.

The most widely used. It goes: one day on, two days off, repeat. So you might dose on Monday, rest Tuesday and Wednesday, dose again Thursday, and so on. The logic is that rest days prevent tolerance from building up and give you a baseline to compare against. Most people run a Fadiman cycle for four to eight weeks before taking an extended break.

[INTERNAL LINK: The Fadiman Protocol: What It Is and How It Works]

A more recent variation developed by mycologist Paul Stamets. It combines a psilocybin microdose with lion's mane mushroom — a functional mushroom studied for its potential effects on nerve growth — and niacin. The proposed mechanism is that niacin helps distribute the other compounds more effectively across the body. The stack has a large following, though direct clinical evidence for this specific combination is limited.

[INTERNAL LINK: What Is a Microdosing Stack? The Paul Stamets Protocol Explained]

Other protocols exist — some people dose every other day, some once a week — but Fadiman and Stamets are the two most documented and most frequently referenced in research.

Survey data from thousands of microdosers consistently points to the same cluster of reported benefits: improved mood, reduced anxiety, better focus, and increased creative thinking. These are the outcomes that drove the original wave of interest, and they remain the most commonly cited reasons people start.

The research picture is more nuanced. A 2019 longitudinal study by Vince Polito at Macquarie University — one of the first peer-reviewed studies to track microdosers over time — found clear positive effects on depression, stress, and concentration. Notably, it found no evidence of the creativity improvements that many microdosers expect, which points to a gap between anecdotal claims and measured outcomes.

More recent research has found some signal on mood and wellbeing that holds up even in controlled conditions, but the placebo effect remains a live methodological question. A 2021 self-blinding study from Imperial College London found that participants who took placebos also improved meaningfully — though the microdose group showed some effects the placebo group did not.

[INTERNAL LINK: What Is Microdosing Research Actually Showing?] [INTERNAL LINK: Microdosing Benefits: What Users Report]

/

Microdosing is not without downsides, and an honest introduction has to include them.

Some people find that even a small dose produces anxiety, restlessness, or an unpleasant heightening of stress rather than a reduction. This appears more common at slightly higher doses and in people who are prone to anxiety to begin with. Lowering the dose or changing the schedule often helps, but it doesn't work for everyone.

Both psilocybin and LSD are stimulating at the neurological level. Dosing too late in the day — afternoon or evening — can interfere with sleep, even at sub-perceptual levels. Most protocols recommend dosing in the morning for this reason.

Microdosing appears to turn up the volume on whatever emotional state is already present. For people in a stable, positive place, this often feels like an enhancement. For people going through a difficult period, it can intensify negative feelings rather than lifting them.

Psilocybin and LSD act on serotonin receptors throughout the body, not just the brain. There is some concern — primarily theoretical, but not trivial — that long-term, repeated activation of certain serotonin receptors could have effects on heart valve tissue. This is an area of ongoing research. People with existing heart conditions should consult a doctor before considering microdosing.

People with a personal or family history of psychosis, schizophrenia, or bipolar disorder are advised not to microdose. Even sub-perceptual doses carry meaningful risk for this population.

In most of the world, including most of the United States, psilocybin and LSD are Schedule I controlled substances — meaning possession is illegal regardless of dose size. There are no legal exceptions for microdosing specifically.

A growing number of US cities have decriminalized psilocybin mushrooms — meaning possession is a low enforcement priority — including Denver, Oakland, Seattle, and Washington D.C. Oregon and Colorado have gone further, establishing regulated frameworks for supervised psilocybin use, though these are designed for therapeutic settings rather than personal microdosing.

The legal landscape is shifting, but slowly. Anyone considering microdosing should understand their local legal context clearly before proceeding.

[INTERNAL LINK: Is Microdosing Legal? What You Need to Know]

/

Psychedelic therapy — the clinical model being developed by researchers at institutions like Imperial College London and Johns Hopkins — involves full doses of psilocybin administered in a controlled setting, with trained therapists present before, during, and after the session. The experience is intense, often profoundly so. The therapeutic model argues that the full psychedelic experience itself — the dissolution of the ordinary sense of self, the unusual perspective it produces — is a key part of how it works.

Microdosing is the opposite approach: small, regular doses specifically chosen to avoid any of that. The two practices have different mechanisms, different evidence bases, and different risk profiles. Research into one doesn't directly apply to the other.

[INTERNAL LINK: What Is Psychedelic-Assisted Therapy?] [INTERNAL LINK: Psilocybin for Depression: What the Research Actually Shows]

Survey data and academic research paint a consistent picture. The average microdosing study participant is educated, employed, and dealing with some level of depression or anxiety — not a recreational drug user looking for a high. Many report trying microdosing after conventional treatments failed or produced unwanted side effects. A significant proportion have no prior experience with psychedelics at full doses.

This demographic shift matters for how microdosing gets discussed. The conversation has moved well beyond Silicon Valley productivity culture into mainstream mental health territory — which is both why the research interest has accelerated and why accuracy about what the evidence does and doesn't show matters more than ever.

Microdosing is a real practice with a real evidence base — and real limits to that evidence base. The reported benefits, particularly around mood and focus, are consistent enough across surveys and early studies to take seriously. The research is not yet at the level where a clinician would recommend it as a treatment, and the legal status in most places remains a practical obstacle.

What microdosing represents, at minimum, is a legitimate area of scientific inquiry that has attracted serious attention from serious researchers. Whether it will eventually earn a formal clinical role — as an adjunct to therapy, a mood management tool, or something else — depends on trials currently underway.

For now, the honest answer is: promising, early, and worth understanding clearly.

[INTERNAL LINK: How to Microdose Psilocybin: A Step-by-Step Guide]